Arcutis Biotherapeutics, Inc.: Q3 FY2025 earnings call

What management said about Q3 FY2025, from the documents filed with the SEC on 28 October 2025: press release. Guidance figures: 3 new. The quarter’s numbers.

Read the filing

Key takeaways

• Product revenue up 122% year over year: Product revenue was $99.2 million, up from $44.8 million a year earlier and up 22% from the second quarter. Management attributed the year-over-year increase primarily to increased unit demand. Source
• Sequential growth from demand and pricing: Management named increasing demand across products, the launch of ZORYVE foam 0.3% in plaque psoriasis of the scalp and body, and improved gross-to-net pricing as sources of sequential growth. Source
• 2026 revenue guidance initially set: The company provided initial full-year 2026 net product sales guidance of $455 million to $470 million. Source
• Cream 0.05% approved for ages 2 to 5: The FDA approved ZORYVE cream 0.05% for atopic dermatitis in children down to 2 years of age in October, extending use to the youngest age group in the label. Source
• Cash and securities fell from year-end: Cash, cash equivalents, restricted cash and marketable securities were $191.4 million at September 30, 2025, down from $228.6 million at December 31, 2024. Source
• Peak ZORYVE sales target stated: Management set a potential peak ZORYVE sales range of $2.6 billion to $3.5 billion per annum, based on an assumed 15% to 20% share of topical corticosteroid volume. Source
• Phase 2 trials in vitiligo and HS: Enrollment has begun in Phase 2 proof-of-concept studies of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, the first trials in the expansion effort. Source

“Over the past nine years, we have built Arcutis into an undisputed leader in medical dermatology.”

Frank Watanabe, president and chief executive officer

Guidance

What changed from last quarter

• New guidance: Initial full-year 2026 net product sales guidance of $455 million to $470 million was provided in this release. Source
• New: ZORYVE cream 0.05% was approved by the FDA for atopic dermatitis in children down to 2 years of age, in October 2025. Source
• New: An Investor Day presented a strategy covering ZORYVE growth, pipeline, capital allocation and a peak ZORYVE sales range. Source

Revenue growth and drivers

• Product revenue up 122% year over year: Product revenue was $99.2 million, up from $44.8 million a year earlier and up 22% from the second quarter. Management attributed the year-over-year increase primarily to increased unit demand. Source
• Sequential growth from demand and pricing: Management named increasing demand across products, the launch of ZORYVE foam 0.3% in plaque psoriasis of the scalp and body, and improved gross-to-net pricing as sources of sequential growth. Source
• Net income against prior-year loss: The company reported net income of $7.4 million, or $0.06 per share, compared with a net loss of $41.5 million, or $0.33 per share, a year earlier. Source
• 2026 revenue guidance initially set: The company provided initial full-year 2026 net product sales guidance of $455 million to $470 million. Source

ZORYVE product mix and approvals

• Foam 0.3% the largest product line: Of the three ZORYVE products reported, foam 0.3% had the largest revenue in the quarter, ahead of cream 0.3% and cream 0.15%. Source
• Cream 0.05% approved for ages 2 to 5: The FDA approved ZORYVE cream 0.05% for atopic dermatitis in children down to 2 years of age in October, extending use to the youngest age group in the label. Source
• Cream 0.05% launch timed for October: Following the approval, the company said it will launch ZORYVE cream 0.05% for children ages 2 to 5 by the end of October. Source

“With ZORYVE, we have developed a portfolio of revolutionary topical treatments that are reshaping the treatment of chronic inflammatory skin diseases and demonstrating sustainable commercial momentum across all strengths and indications,”

Frank Watanabe, president and chief executive officer

Gross-to-net, pricing and cost of sales

• Gross-to-net rates stayed favorable: Management said gross-to-net rates remained favorable, which it linked to a high percentage of prescriptions being reimbursed. Source
• Gross-to-net improved sequentially: Improved gross-to-net pricing was one of the three stated drivers of the sequential increase in ZORYVE sales over the second quarter. Source
• Cost of sales rose with ZORYVE sales: Cost of sales was $8.7 million, compared with $5.5 million a year earlier, which the company attributed to increasing ZORYVE sales. Source

Operating expenses

• R&D flat as programs shifted: R&D expense was $19.6 million, close to the prior year. Higher pediatric atopic dermatitis costs were offset by lower ARQ-255 and preclinical costs. Source
• SG&A rose on commercial spending: SG&A expense was $62.4 million, compared with $58.8 million a year earlier, driven by sales and marketing and personnel costs for ZORYVE commercialization. Source
• Operating income against prior-year loss: Income from operations was $8.5 million in the quarter, compared with a loss from operations of $39.1 million a year earlier. Source

“This success provides a tremendous foundation for sustained, long-term growth”

Frank Watanabe, president and chief executive officer

Cash, balance sheet and receivables

• Cash and securities fell from year-end: Cash, cash equivalents, restricted cash and marketable securities were $191.4 million at September 30, 2025, down from $228.6 million at December 31, 2024. Source
• Operating cash use in quarter: Net cash used in operating activities was $1.8 million in the third quarter, compared with $0.3 million provided in the second quarter. Source
• Receivables and inventories increased: Trade receivables were $115.1 million, up from $73.1 million at December 31, 2024, and inventories were $22.4 million, up from $14.5 million. Source

Strategy and peak sales target

• Peak ZORYVE sales target stated: Management set a potential peak ZORYVE sales range of $2.6 billion to $3.5 billion per annum, based on an assumed 15% to 20% share of topical corticosteroid volume. Source
• Growth through steroid market conversion: Management described continued conversion of the topical corticosteroid market as a growth route, citing 17 million annual prescriptions in ZORYVE-approved indications. Source

Indication expansion and pipeline

• Phase 2 trials in vitiligo and HS: Enrollment has begun in Phase 2 proof-of-concept studies of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, the first trials in the expansion effort. Source
• Pipeline built through ARQ-234 and deals: Management said pipeline building will proceed through advancing ARQ-234 and potentially through external innovation. Source
• ARQ-234 Phase 1 study in preparation: The company is preparing a Phase 1 study of ARQ-234, a CD200 receptor checkpoint agonist fusion protein being developed for atopic dermatitis. Source

Corporate recognition and patents

• One new U.S. patent obtained: The company obtained one new U.S. patent in the third quarter of 2025 related to topical roflumilast foam compositions. Source
• Allure award for ZORYVE products: ZORYVE cream and foam received Allure's 2025 Best of Beauty Breakthrough Award, described as the first such award for an FDA-approved atopic dermatitis, plaque psoriasis and seborrheic dermatitis medication. Source
• Fortune workplace listing for fourth year: Arcutis was named to the Fortune Best Workplaces in BioPharma 2025 list for the fourth consecutive year. Source

Coming up, as management said on 28 October 2025

• ARQ-234 Phase 1 start in preparation: Management said the company is preparing to initiate a Phase 1 study of ARQ-234. No start date was given. Source
• Investor Day webcast replay posted: A replay of the Investor Day webcast will be posted on the Arcutis website after the event. Source

Figures management reported

Earlier plans management reported on

• Not stated: The prior release expected a potential Q4 approval. This release reports FDA approval received in October, without describing the expectation as met.

Other quarters

• Q3 FY2026 earnings call
• Q2 FY2026 earnings call
• Q1 FY2026 results
• Q4 FY2025 earnings call

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.